Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Research letter describes American prospective cohort study (n=436) in which transplant recipients receiving maintenance immunosuppression therapy were less likely to develop an antibody response vs those not receiving such immunosuppression (37% vs 63%, respectively; P <0 .001).

Source:

Journal of the American Medical Association